Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes

NCT01399645 on ClinicalTrials.gov · last registry update 2014-08-27

A small phase 2 — 35 participants, against a typical 110. The sponsor logged completion for June 2014. Primary outcome, as filed: To determine liver fat fraction evolution induced by liraglutide and insulin. liraglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Sponsor type: Other
Enrollment: 35
Started: 2011-05
Primary completion: 2014-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

To determine liver fat fraction evolution induced by liraglutide and insulin

Conditions studied

Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis · Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.